Physician profile
William Mcelhaugh
NPI 1427031079
$896.93
in general payments reported to CMS, 2019-2025
17 companies · $355 in 2025
The $355 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.78 · 2020: $133 · 2021: $64.75 · 2022: $19.73 · 2023: $125 · 2024: $134 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $613.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $140.81 | 2024-2025 | Ibsrela |
| Amgen INC. | $112.50 | 2019-2025 | Tavneos |
| Aurinia Pharma U.S., INC. | $86.17 | 2023-2025 | Lupkynis |
| Lilly USA, LLC | $80.87 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $80.70 | 2020-2021 | |
| Fresenius USA Marketing, INC. | $68.73 | 2020-2023 | Velphoro |
| Calliditas Therapeutics US INC. | $54.33 | 2024-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $52.91 | 2025 | |
| Akebia Therapeutics INC | $37.69 | 2023-2024 | Auryxia |
| Bayer Healthcare Pharmaceuticals INC. | $36.78 | 2025 | |
| Daiichi Sankyo INC. | $23.26 | 2019 | |
| Novo Nordisk INC | $23.01 | 2025 | Ozempic |
| Apellis Pharmaceuticals, INC. | $22.88 | 2025 | Empaveli |
| Otsuka America Pharmaceutical, INC. | $22.50 | 2021 | |
| Glaxosmithkline, LLC. | $19.76 | 2024 | Benlysta |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $18.54 | 2025 | Rayaldee |
| Vifor Pharma, INC. | $15.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mcelhaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.